
|Articles|May 21, 2019
Xcenda Announces Acquisition of Dymaxium
Advertisement
Xcenda, a part of AmerisourceBergen, has acquired Dymaxium, a market access partner specializing in the exchange of evidence and information between payers and life science companies.
This acquisition will further simplify and streamline the necessary communication of clinical evidence and health economic information between manufacturers and population health decision makers.
Newsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Novo Nordisk Submits Higher-Dose Wegovy Injectable for FDA Approval with Priority Voucher
2
Novartis Planning Layoffs for 550 Positions at Switzerland Facility
3
How Will FDA's Priority Review Program Impact Domestic Manufacturing?
4
What Trends Do You See in Neuroscience in 2026?
5





